Flavonoids Inhibit Cancer by Regulating the Competing Endogenous RNA Network

Chengshun Li†, Xiaolan Li‡, Ziping Jiang‡, Dongxu Wang†, Liqun Sun§, Jiaqi Li§ and Yang Han†

† Laboratory Animal Center, College of Animal Science, Jilin University, Changchun, China, ‡ State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China, § Department of Hand and Foot Surgery, The First Hospital of Jilin University, Changchun, China

Flavonoids are present in a wide range of plants. They have been used in the treatment of cancer, but the mechanism underlying this activity is unclear. In recent years, microRNA (miRNA) and long non-coding RNA (lncRNA) levels have been observed to differ between normal tissues and cancer cells, and both types of RNA have been shown to have a role in tumor treatment. In addition, flavonoids have been proven to regulate miRNAs and LncRNAs in the treatment of cancer. The competing endogenous RNA (ceRNA) network is a complex post-transcriptional regulatory mechanism in cells, in which coding and non-coding RNAs competitively bind miRNAs to regulate messenger RNAs (mRNAs). This review focused on the role of the ceRNA network in the treatment of cancer by flavonoids.

Keywords: flavonoids, gastric cancer, miRNA, lncRNA, the competing endogenous RNA network

INTRODUCTION

Flavonoids are a group of polyphenol compounds, including flavones, flavanols, chalcone and others, with a C6-C3-C6 structure (1). They are widely distributed in nature, mainly in plants and fruit. For instance, chrysin is found in the stems and seeds of plants in the family Bignoniaceae and Pinus bungeana. There is growing evidence that a range of flavonoids have strong pharmacological effects, such as anti-inflammatory, vascular protective, anti-oxidative, and anti-viral properties (2, 3). A study performed that dietary flavonoid intake is associated with a reduced risk of different types of cancer, such as gastric, breast, prostate, and colorectal cancers (4). A few studies have also demonstrated an important role of flavonoids in cancer treatment by mechanisms such as inducing apoptosis and inhibiting proliferation. Flavones, such as vitexin can suppress melanoma cell growth (5), chrysin and luteolin can induced apoptosis in HeLa cells (6, 7). Myricetin, as a member of flavonols, can prevent the incidence of colorectal tumorigenesis and reduce the size of colorectal polyps (8). Flavanonol taxifolin can inhibit the migration and invasion of breast cancer cells (9). These evidences suggest that various flavonoids have positive effects on anti-cancer.

The competing endogenous RNA (ceRNA) hypothesis was initially proposed in 2011 (10). It suggested that various RNAs may regulate each other through microRNAs (miRNAs). Previous studies usually focused only on the unidirectional regulation between miRNA and target genes. It was clear that the mechanism of action of miRNAs involved inhibiting mRNA translation or promoting mRNA degradation (11). The ceRNA hypothesis proposed that RNAs can regulate one another by using the

**Citation:**

Li C, Li X, Jiang Z, Wang D, Sun L, Li J and Han Y (2022) Flavonoids Inhibit Cancer by Regulating the Competing Endogenous RNA Network. Front. Oncol. 12:842790. doi: 10.3389/fonc.2022.842790
same miRNA response elements (MREs) as a molecular sponge to competitively bind miRNAs (12). This advanced our understanding of the function of non-coding RNAAs (ncRNAs). A large part of the human transcriptional genome comprises ncRNAs, and they have a reported role in cancer. Compared with normal tissues, numerous ncRNAs show differential expression in cancer tissues (13). Previous studies have proved that abnormally expressed long ncRNAs (LncRNAs) can promote cancer through the ceRNA network, whereas reversing the expression of LncRNAs can inhibit tumor growth (14–16).

In addition, sequencing results have shown that flavonoids, such as galangin, baicalein, chrysin, can change the expression level of mRNAs in tumors, as well as causing the differential expression of miRNAs and LncRNAs (https://www.ncbi.nlm.nih.gov/geo/). These evidences suggest that the anti-cancer mechanism of flavonoids may be related to the regulation of the ceRNA network (Figure 1).

**miRNAs AND THE ceRNA NETWORK**

miRNAs are small single-stranded ncRNAs with a length of about 20 nucleotides (nt) (17). After a series of processing steps from the nucleus to the cytoplasm, miRNAs finally mature and assemble with Argonaute (Ago) family proteins to form the RNA-induced silencing complex (RISC) (18, 19). The parts of the target transcript that complement the miRNA sequences are called MREs; they are specifically recognized by miRNAs and guide the RISC to target RNAs, thereby either inhibiting the translation or inducing the degradation of the target mRNA. In humans, the base pairing between miRNAs and their targets is not usually highly specific, which makes the regulatory ability of miRNAs more extensive (20). With the progress of sequencing technology, numerous miRNAs have been characterized and differential changes have been found in various cancers (21). In this context, microRNAs are usually divided into two categories: carcinogenic miRNAs, which are generally highly expressed in tumors, inhibit tumor-suppressor genes, and promote the occurrence and development of tumors, such as miR-675 (22) and miR-501-5p (23); and tumor-suppressor miRNAs, such as miR-199a-3p (24) and miR-101 (25). Notably, the role of miRNAs has tissue specificity. For example, miR-125b can inhibit cell proliferation and induce apoptosis in colon cancer, and participate in tumor drug-resistance in hepatocellular carcinoma (HCC) (26, 27). miRNAs are central to the ceRNA network, through which RNAs can regulate others with similar MRE communication. In addition, a recent study found that the flavonoid scutellarin could alter the miRNA-expression profile of hepatoma cells (28). These findings suggest that regulating miRNA expression is an important mechanism-of-action of flavonoids in cancer treatment.

**LncRNAs AS MOLECULAR SPONGES IN THE ceRNA REGULATORY NETWORK**

LncRNAs are ncRNAs with a length of more than 200 bases, which are transcribed by RNA polymerase II. Although LncRNAs do not encode proteins, they have a variety of biological functions, including gene activation and silencing, alternative splicing, and post-translational modification (29, 30).

On the one hand, LncRNAs can form miRNA precursors through intracellular shear and further progress into mature miRNAs. On the other hand, as an important part of the ceRNA network, LncRNAs are rich in MREs, which allows them to act as a molecular sponge to competitively bind miRNAs and regulate their targets.

A large number of differentially expressed LncRNAs have been found in cancer. Similar to miRNAs, LncRNAs can be divided into cancer-promoting and cancer-inhibiting types. The most common oncogenic LncRNA-H19 was one of the first to be described (31), and has been proved to be overexpressed in many cancers. H19 overexpression in bladder cancer cells reduces E-cadherin, thereby promoting cell migration and invasion (32), and promotes the epithelial-to-mesenchymal transition in colorectal cancer by absorbing miR-138 and miR-200a (33). In addition, LncRNAs such as LncRNA00364 and NCALD can inhibit the proliferation and progression of HCC cells (34). Evidence suggests that the abnormal expression of LncRNAs in cancer can be reversed by flavonoids, and has an inhibitory effect on cancer (35). This indicates that flavonoids can regulate the expression of LncRNAs for cancer treatment.

**mRNAs ARE BOTH REGULATORS AND REGULATED IN THE ceRNA NETWORK**

Because mRNAs are eventually translated into proteins that play biological roles, they often appear to be the main targets of regulation in the ceRNA network; however, they can also participate in the post-transcriptional regulation of other genes, which complicates the crosstalk (36). mRNAs can regulate key genes in carcinogenesis and development in an mRNA-dependent manner. HMG2A can increase the expression of TGFBR3 as a molecular sponge of the let-7a family to promote the occurrence of lung cancer (37). A previous study predicted that NCALD may affect drug resistance and prognosis in ovarian cancer by acting as a ceRNA of CX3CL1 for tumor suppression (38). A large number of reports have shown that flavonoids can regulate mRNAs in tumors to inhibit their progression, and some mRNAs have been proven to be regulated by miRNAs that are affected by flavonoids (39, 40). In conclusion, mRNAs play a prominent role in the anti-cancer effect of flavonoids, and flavonoids can inhibit cancer by regulating mRNAs directly and indirectly.

**FLAVONOIDs CAN INHIBIT CANCER THROUGH THE ceRNAsNETWORK**

Numerous studies have shown that flavonoids play a positive role in the treatment of cancer (41, 42). There are evidences that flavonoids can inhibit various kinds of cancer in many different...
Flavonoids inhibit cancer through the ceRNA network. Flavonoids promote miRNA production, then regulate the ceRNA network, and finally regulate the physiological function of cancer cells via various pathways.
**FIGURE 2** | The role of chrysin in gastric cancer through the ceRNA network. (A) The structure of chrysin. (B, C) LncRNAs and mRNAs that were upregulated in STAD but reversed by chrysin. (D, E) LncRNAs and mRNAs that were downregulated in STAD but reversed by chrysin. (F) Intersection of the miR6739 target gene and the genes reversed by chrysin in gastric cancer. (G, H) Enrichment for Kyoto Encyclopedia of Genes and Genomes (KEGG) and KEGG Orthology (GO) gene sets of the genes reversed by chrysin. (I) Enrichment of KEGG and GO gene sets of the target genes of miR-6739.
ways (43–45). Flavonoids can affect both coding RNAs and ncRNAs in cancer cells, suggesting that the regulation of the ceRNA network is involved in the inhibitory effect of flavonoids on the occurrence and development of cancer. Our previous study suggested that chrysin could promote the apoptosis of gastric cancer cells through the H119/miR-Let-7a/COPB2 axis (16). Furthermore, as a kind of flavonoids, quercetin can inhibit proliferation and invasion by up-regulating miR-146a in human breast cancer cells (46), and increase the sensitivity of non-small-cell lung cancer cells to radiotherapy by regulating the miR-16-5p/WEE1 axis (47). Aside from inhibiting cancer, flavonoids can reverse drug resistance through the ceRNA network.

We further analyzed the sequencing data of gastric cancer cells treated with chrysin (Gene Expression Omnibus [GEO] accession: GSE181492). The results showed that chrysin could regulate the mRNA expression of nuclear factor kappa B (NFκB), p53, and other signaling pathways, which may be a key link in the complex anticancer effect of chrysin (Figure 2). Moreover, we found that some LncRNAs, miRNAs, and mRNAs were expressed abnormally in stomach adenocarcinoma (STAD), but the reverse pattern was seen in gastric cancer cells treated with chrysin. Notably, only miR-6739 was found to have a rescue effect on chrysin in the sequencing results. It was upregulated in gastric cancer and downregulated after chrysin treatment. This indicated that miRNA may play key roles in the chrysin treatment of gastric cancer. According to the prediction of its direct target gene by MREs, chrysin may inhibit gastric cancer via miR-6739 through peroxisome proliferator-activated receptor (PPAR) and other pathways.

**DISCUSSION**

Existing cancer treatment mainly involves surgical resection supplemented by chemotherapy. Apart from having side-effects for patients, chemotherapy also has an important limitation in terms of drug resistance. However, some of the members of flavonoids can reverse drug resistance of cancers by various ways. For example, baicalein can increase cisplatin sensitivity of A549 lung adenocarcinoma cells (48). Luteolin can enhance chemosensitivity of breast cancer through the Nrf2-Mediated pathway (49). Quercetin can increase the chemosensitivity of breast cancer to doxorubicin Via PTEN/Akt pathway (50). Therefore, flavonoids might be used to reduce the side-effects of chemotherapy drugs and increase the sensitivity of tumors. Studies have shown that abnormal miRNA and LncRNA expression can cause drug resistance in cancer (51, 52). The flavonoids mentioned above may reverse drug resistance with the help of the ceRNA network; flavonoids may therefore be used to reduce the side-effects of chemotherapy drugs and increase the sensitivity of tumors, in order to treat cancer more safely and effectively. In addition, there is evidence that quercetin, chrysin, luteolin and other flavonoids contribute to wound healing (53), which may aid patients’ postoperative recovery. These make flavonoid drugs have a better prospect in the combination of other drugs in the treatment of cancer.

In conclusion, the ceRNA network plays an important role in cancer treatment with flavonoids. Flavonoids can regulate cancer-related genes via the ceRNA network. Moreover, the ceRNA network can have additional effects that may help patients with treatment and recovery. These findings show that the ceRNA network offers new prospects for the use of flavonoids in anti-cancer treatment.

**AUTHOR CONTRIBUTIONS**

CL and DW wrote the manuscript. CL, XL, ZJ, LS, YH, and JL collected the references and prepared figures. All authors reviewed the manuscript. All authors contributed to the article and approved the submitted version.

**FUNDING**

This work was supported by Natural science Foundation of the Jilin province (20210101310JC) and Chinese Postdoctoral International Exchange Program.

**REFERENCES**

1. Pei R, Liu X, Bolling B. Flavonoids and Gut Health. *Carr Opin Biotechnol* (2020) 61:153–9. doi: 10.1016/j.copbio.2019.12.018
2. Maleki SJ, Crespo JF, Cabanillas B. Anti-Inflammatory Effects of Flavonoids. *Food Chem* (2019) 299:125124. doi: 10.1016/j.foodchem.2019.125124
3. Ciumânaréan L, Milăcu MV, Runcan O, Vesa ŠC, Răchișan AL, Negrea V, et al. The Effects of Flavonoids in Cardiovascular Diseases. *Molecules* (2020) 25(18):4320. doi: 10.3390/molecules25184320
4. Rodríguez-García C, Sánchez-Quesada C, Gaforio JJ. Dietary Flavonoids as Cancer Chemopreventive Agents: An Updated Review of Human Studies. *Antioxidants (Basel)* (2019) 8(5):137. doi: 10.3390/antiox8050137
5. Liu N, Wang KS, Qi M, Zhou YJ, Zeng GY, Tao J, et al. Vitexin Compound 1, a Novel Extraction From a Chinese Herb, Suppresses Melanoma Cell Growth Through DNA Damage by Increasing ROS Levels. *J Exp Clin Cancer Res* (2018) 37(1):269. doi: 10.1186/s13046-018-0897-x
6. Raina R, Afroz N, Kedhari Sundaram M, Haque S, Bajbouj K, Hamad M, et al. Chrysin Inhibits Propagation of Hela Cells by Attenuating Cell Survival and Inducing Apoptotic Pathways. *Eur Rev Med Pharmacol Sci* (2021) 25(5):2206–20. doi: 10.26355/eurrev_202103_25253
7. Raina R, Pramodh S, Rais N, Haque S, Shafran I, Bajbouj K, et al. Luteolin Inhibits Proliferation, Triggers Apoptosis and Modulates Akt/Mtor and Map Kinase Pathways in Hela Cells. *Oncol Lett* (2021) 21(3):192. doi: 10.3892/ol.2021.12452
8. Zhang MJ, Su H, Yan JY, Li N, Song ZY, Wang HJ, et al. Chemopreventive Effect of Myricetin, a Natural Occurring Compound, on Colonic Chronic Inflammation and Inflammation-Driven Tumorigenesis in Mice. *BioMed Pharmacother* (2018) 97:1131–7. doi: 10.1016/j.biopha.2017.11.018
9. Li J, Hu L, Zhou T, Gong X, Jiang R, Li H, et al. Taxifolin Inhibits Breast Cancer Cells Proliferation, Migration and Invasion by Promoting Mesenchymal to Epithelial Transition Via B-Catenin Signaling. *Life Sci* (2019) 232:116617. doi: 10.1016/j.lfs.2019.116617
10. Salmenal.A,Poliseno.L,Tay,Y,Kat.„Dis.Pandolfo.P.A,AcmaHypothesis:TheRosettaStoneofaHiddenRnaLanguage?Cell(2011)146(3):353–8.doi:10.1016/j.cell.2011.07.014
11. Cai Y, Yu X, Hu S, Yu J. A Brief Review on the Mechanisms of Mirna Regulation. *Genomics Proteomics Bioinf* (2009) 7(4):147–54. doi: 10.1016/s1672-0229(08)60044-3
12. Karreth FA, Pandolfi PP. Cerna Cross-Talk in Cancer: When Ce-Bling Rivalries Go Aver. Cancer Discov (2013) 3(10):1113–21. doi: 10.1158/2159-8290.Cd-13-0502
13. Slack FJ, Chinnaiyan AM. The Role of Non-Coding Rnas in Oncology. Cell (2019) 179(5):1633–55. doi: 10.1016/j.cell.2019.10.017
14. Chen, Li Q, Jiang Z, Li C, Hu H, Wang T, et al. Chrs Er-Induced Cell Apoptosis Through M16/let-7a/Cop62 Axis in Gastric Cancer Cells and Inhibited Tumor Growth. Front Oncol (2021) 11:651644. doi: 10.3389/fonc.2021.651644
15. Kong X, Duan Y, Sang Y, Li Y, Zhang H, Liang Y, et al. Lncrna-Cdc6 Promotes Breast Cancer Progression and Function as Cerna to Target Cdc6 by Sponging Microrna-215. J Cell Physiol (2019) 234(6):9105–17. doi: 10.1002/jcp.27587
16. Li H, Wang X, Wen C, Huo Z, Wang W, Zhan Q, et al. Long Noncoding Rna Norad, a Novel Competing Endogenous Rna, Enhances the Hypoxia-Induced Epithelial-Mesenchymal Transition to Promote Metastasis in Pancreatic Cancer. Mol Cancer (2017) 16(1):169. doi: 10.1186/s12943-017-0738-0
17. Zealy RW, Wrenn SP, Davila S, Min KW, Yoon JH. Microrna-Binding Proteins: Specificity and Function. Wiley Interdiscip Rev RNA (2018) 7 (5):10. doi: 10.1002/wrna.1414
18. Lee Y, Jeon K, Lee JT, Kim S, Kim VN. Microrna Maturation: Stepwise Processing and Subcellular Localization. EMBO J (2002) 21(17):4663–70. doi: 10.1093/emboj/cdf476
19. Kobayashi H, Tomari Y. Risc Assembly: Coordination Between Small Rnas and Argonaute Proteins. Biochim Biophys Acta (2016) 1859(1):71–81. doi: 10.1016/j.bbadis.2015.08.007
20. Dong C, Yin F, Zhu D, Cai X, Chen C, Liu X. Cerna Cross-Talk in Cancer: When Ce-Bling Rivalries Go As a Cerna of Cx3cl1 in Ovarian Cancer. J Cell Biochem (2020) 121(11):4740–83. doi: 10.1002/jcb.29670
21. Zhong X, Liu D, Jiang Z, Li C, Chen L, Xia Y, et al. Chrs Er-Induced Cell Apoptosis and Inhibited Invasion Through Regulation of Tet1 Expression in Gastric Cancer Cells. Onco Targets Ther (2020) 13:3277–87. doi: 10.2147/ OTT.S228603
22. Bhat FA, Sharmila G, Balakrishnan S, Arunkumar P, Suganya S, et al. Quercetin Inhibits Efl-Induced Epithelial to Mesenchymal Transition and Invasiveness in Prostate Cancer (Pc-3) Cell Line Via Egrf/Pik3/Akt Pathway. J Nutr Biochem (2014) 25(11):1332–9. doi: 10.1016/j.jnutbio.2014.06.008
23. Lim W, Ryu S, Bazer FW, Kim SM, Song G. Chrs Er Attenuates Progression of Ovarian Cancer Cells by Regulating Signaling Cascades and Mitochondrial Dysfunction. J Cell Physiol (2018) 233(4):3129–40. doi: 10.1002/jcp.26150
24. Shaikhu S, Shyam H, Agarwal S, Sharma R, Nag TC, Dwivedi AK, et al. Genistein Potentiates Centchroman Induced Antineoplasticity in Breast Cancer Via Pik3/Akt Deactivation and Ros Dependent Induction of Apoptosis. Life Sci (2019) 239:117073. doi: 10.1016/j.lfs.2019.117073
25. Li K, Zheng Q, Chen X, Wang Y, Wang D, Zhang J. Isobavachalcone Induces Ros-Mediated Apoptosis Via Targeting Thioredoxin Reductase 1 in Human Prostate Cancer Pc-3 Cells. Oxid Med Cell Longev (2018) 2018:1915828. doi: 10.1155/2018/1915828
26. Shi J, Chen Y, Chen W, Tang Z, Zhang H, Chen Y, et al. Isobavachalcone Sensitizes Cells to E2-Induced Paclitaxel Resistance by Down-Regulating Cing44 Expression in Her2 Breast Cancer Cells. J Cell Mol Med (2018) 22 (11):5220–30. doi: 10.1111/jcmm.13719
27. Liu HE, Jiang EK, Bang C, Kim GH, Yoon SY, Lee DH, et al. Bakuchoil, Main Component of Root Bark of Ulmus Davidiana Var. Japonica, Inhibits Cing-B-Induced in Vitro Apoptosis and In Vivo Metastasis. Arch Biochem Biophys (2021) 709:108969. doi: 10.1016/j.abb.2021.108969
28. Tao SF, He HF, Chen Q, Quercetin Inhibits Proliferation and Invasion Acts by Up-Regulating Mir-146a in Human Breast Cancer Cells. Mol Cell Biochem (2015) 402(1-2):93–100. doi: 10.1007/s11010-014-2317-7
29. Wang Q, Chen Y, Hu L, Wang H, Fang X, et al. Quercetin Sensitive Cells of Non-Small Cell Lung Cancer Cells Through the Regulation of Mir-16-5p/Weel I Axis. JN utr Biochem (2021) 85:100. doi: 10.1016/j.jnutbio.2021.09.038
30. Wang Q, Chen Y, Hu L, Wang H, Fang X, et al. Quercetin Radiosensitizes Non-Small Cell Lung Cancer Cells Through the Regulation of Mir-16-5p/Weel I Axis. JN utr Biochem (2021) 85:100. doi: 10.1016/j.jnutbio.2021.09.038
31. Brannan CI, Dees EC, Ingram RS, Tilghman SM. The Product of the H19 Gene May Function as an Rna. Mol Cell Bioi (1990) 10(1):28–36. doi: 10.1128/mcb.10.1.28-36.1990
32. Zhu Z, Xu L, Wan Y, Zhou J, Fu D, Chao H, et al. Inhibition of E-Cadherin Expression by Lnc-Rna H19 to Facilitate Bladder Cancer Metastasis. Cancer biomark (2018) 22(2):275–81. doi: 10.3233/cbm-170998
33. Liang WC, Fu WM, Wong CW, Wang Y, Wang WM, Hu GX, et al. The Lncrna H19 Promotes Epithelial to Mesenchymal Transition by Functioning as Mrna Sponges in Colorectal Cancer. Oncotarget (2015) 6(26):22513–25. doi: 10.18632/oncotarget.14154
34. Mohan CD, Ranagapa MR, Nayan SC, Sethi G, Ranagappa KS. Paradoxical Functions of Long Noncoding Rnas in Modulating Stat3 Signaling Pathway in Hepatocellular Carcinoma. Biochim Biophys Acta Rev Cancer (2021) 1876 (1):188574. doi: 10.1016/j.bbcan.2021.188574
35. Lu X, Chen D, Yang F, Xing N. Quercetin Inhibits Epithelial-To-Mesenchymal Transition (Emt) Process and Promotes Apoptosis in Prostate Cancer Via Downregulating Lncrna Malat1. Cancer Manag Res (2020) 12:1741–50. doi: 10.2174/cmcr.2021.184754
36. Kumar MS, Armenteros-Montorero E, East P, Chakravorty P, Matthews N, Winslow MM, et al. Hmg2 Functions as a Competing Endogenous Rna to Promote Lung Cancer Progression. Nature (2014) 505(7482):212–7. doi: 10.1038/nature12785
37. Dong C, Yin F, Zhu D, Cai X, Chen C, Liu X. Ncald Affects Drug Resistance and Prognosis by Acting as a Cerna of Cx3cl1 in Ovarian Cancer. J Cell Biochem (2020) 121(1):4740–83. doi: 10.1002/jcb.29670
38. Li et al. Flavonoids Inhibit Cancer With ceRNA
39. Li et al. Flavonoids Inhibit Cancer With ceRNA
53. Carvalho MTB, Araújo-Filho HG, Barreto AS, Quintans-Júnior LJ, Quintans JSS, Barreto RSS. Wound Healing Properties of Flavonoids: A Systematic Review Highlighting the Mechanisms of Action. *Phytotherapy* (2021) 90:153636. doi: 10.1016/j.phymed.2021.153636

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Li, Li, Jiang, Wang, Sun, Li and Han. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.